FABP1 and metabolic dysfunction-associated steatotic liver disease: A previous study (8) has found that FABP1 can play a negative regulatory role in the formation of very-low-density lipoproteins, which can lead to lipid metabolism disorders when combined with total cholesterol, triglycerides, and apolipoprotein B, thereby accelerating NAFLD progression.